ASX shares have rebounded over the past month as inflation and interest-rate concerns have eased.

At the time of writing, the All Ordinaries Index (ASX: XAO) is up around 0.5% for the day. The index is also 3% higher year to date.

The increase is great news for investors, but now many have their eye focused on which ASX shares could climb even higher over the next 12 months.

Here are three stocks which are tipped to outperform the index, and they’re all forecast to jump up to 66% higher.

Catalyst Metals Ltd (ASX: CYL)

Catalyst Metals shares are down around 1.5% and trading at $6.46 a piece, at the time of writing. For the year-to-date, the shares are down around 12%.

It’s been a rocky 12 months for the ASX gold producer’s shares.

The share price spiked to an all-time high in January when the company announced a significant new high-grade discovery at its Plutonic Gold Belt. 

But then the gold stock then shed around 52% of its value to an annual low in early-June. The crash followed headwinds from a weaker gold price, higher mining costs and an investor rotation away from gold shares.

But now it looks like a recovery is in sight and the previous headwinds are turning into tailwinds. Catalyst Metals shares have now rebounded around 37% from the June-low.

Catalyst Metals has a long period of operational consistency and organic growth and looking ahead, the miner expects production to increase towards the latter half of FY26 as well. 

Market Index data shows that brokers agree a strong buy rating on the rate the ASX shares. They tip an average target price of $10.75. That implies a potential 66% upside at the time of writing.

Predictive Discovery Ltd (ASX: PDI)

Predictive Discovery has suffered the same headwinds as Catalyst Metals this year. Higher mining costs, weaker gold prices, and an overall investor rotation away from ASX gold shares into larger, more stable assets, has seen a steep investor sell off. 

The shares fell to an eight-month low of 61 cents a piece in mid-July but have now rebounded around 41%. At the time of writing, the shares are up around 1% for the day and changing hands at 86 cents each.

They’re now 17% higher for the year-to-date and a huge 95% higher than 12 months ago.

And the experts think the gold miner’s shares can keep climbing higher too.

Predictive Discovery’s production numbers are expected to increase in the latter half of the year, with the miner actively developing gold deposits in Guinea’s Siguiri Basin. 

Market Index data shows brokers agree to a strong buy rating on the ASX shares. The maximum target price is $1.35 per share, which implies a potential 57% upside at the time of writing.

Judo Capital Holdings Ltd (ASX: JDO)

Judo was one of the strongest-performing bank shares on the ASX earlier this year. But the stock crashed 46 in late-June after it downgraded its profit guidance for FY26. 

The ASX 200 bank stock revealed that its profit before tax in FY26 is now expected to be between $163 million and $169 million (approximately 30% growth on FY25). This is down from the previous guidance of $180 million to $190 million.

But the bank posted its FY26 results ahead of the market open this morning and it seemed to be much better than the market expected. Judo announced strong gains across the board. NPAT increased 29% to $111.1 million and profit before tax increased 34% to $168.1 million, the top end of Judo’s revised guidance range.

Investors are now rushing back into the stock. At the time of writing, the shares are up an impressive 12% for the day so far, and changing hands at $1.02. It means Judo shares have now recovered around 16% of the losses shed in June, but they’re still 43% lower for the year-to-date and 42% lower than this time last year.

It’s clear that the selloff was way overdone and that the bank is growing stronger than many anticipated. Analysts are very bullish that the stock can keep rebounding higher in coming months.

Market Index data shows the majority of brokers have a strong buy rating on the shares. The $1.49 average target price implies a potential upside of around 51%, at the time of writing. 

The post Brokers tip these 3 ASX shares to climb another 50% to 66% appeared first on The Motley Fool Australia.

More reading

• 2 ASX 200 bank stocks making BIG moves today on results
• Judo Capital reports FY26 earnings and upbeat outlook
• Here are the top 10 ASX 200 shares today
• Here are the top 10 ASX 200 shares today
• 4 ASX 200 gold shares to buy: Experts

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

CSL Ltd (ASX: CSL) shares surged 18% to $158.24 in early afternoon trade on Tuesday That’s a welcome change for shareholders after the ASX healthcare stock lost 42% over the past 12 months.

By comparison, the S&P/ASX 200 Index (ASX: XJO) has gained around 2% over the same period.

Investors appear encouraged by CSL’s latest full-year results and, in particular, management’s outlook following what the company describes as a ‘reset year’.

CSL’s reset year

For the year ended 30 June 2026, CSL reported total revenue of US$15.8 billion, down 1% year-over-year. Underlying NPATA fell 2% to US$3.1 billion.

The headline statutory result was considerably weaker, with CSL reporting a net loss after tax of US$2.6 billion. However, this reflected significant one-off costs and impairments.

CSL spent FY26 undertaking a broad transformation program, including about US$176 million in cost savings, the integration of its Behring and Vifor operations and US$799 million in restructuring costs.

The company also booked US$7.1 billion of pre-tax asset impairments, largely reflecting changes to commercial outlooks, generic competition, regulatory developments and site-utilisation assumptions.

What comes next for CSL shares?

Importantly, management expects FY27 to mark a return towards growth. Revenue is forecast to remain broadly steady, while underlying NPAT is expected to increase by approximately 5%.

CSL Behring is expected to deliver mid-single-digit revenue growth, supported particularly by immunoglobulin demand. CSL Seqirus is targeting low-single-digit growth, although softer US immunisation rates remain a headwind.

Vifor, meanwhile, is expected to decline amid generic competition and regulatory changes.

CSL is also continuing to invest for the longer term. The company announced a new US$1.1 billion share buyback and remains focused on developing new therapies and expanding its US plasma manufacturing network.

It has also entered a strategic partnership with VarmX for a novel blood-coagulation treatment.

What did management say?

Interim CEO and Managing Director Gordon Naylor said:

FY26 has been a year of reset. We have taken decisive action and created a clear path to return to sustainable growth.

Plasma market fundamentals and demand remain robust and momentum is building behind our newer therapies, such as ANDEMBRY® and HEMGENIX.

We have made solid progress on our transformation program and continue to simplify the business. We have also invested in our commercial capabilities and development programs to drive top line growth in the future.

For CSL shareholders, the sharp share price rebound suggests the market is willing to look beyond FY26’s difficult numbers and focus instead on the company’s potential return to sustainable growth.

The post CSL shares surge 18% as ‘reset year’ points to a return to growth appeared first on The Motley Fool Australia.

More reading

• Why is everyone talking about CSL, Pro Medicus and BHP shares on Tuesday?
• How to find ASX shares that Warren Buffett might buy
• How much do I need in my superannuation to earn $50,000 per year in passive income?
• WAM Leaders lifts dividend as portfolio outperforms in FY26
• CSL earnings: FY26 sees reset and path to future growth

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Already trading near its all-time highs, the All Ordinaries Index (ASX: XAO) is unlikely to return 30% over the coming year, but this ASX All Ords mining stock is tipped to do just that.

That’s according to the team at wealth manager Euroz Hartleys, who recently reiterated their speculative buy rating on BCI Minerals Ltd (ASX: BCI).

In afternoon trade today, BCI Minerals shares are trading for 46 cents apiece. That’s up 27.8% since this time last year. And it gives the ASX All Ords mining stock a market cap of around $1.35 billion.

Looking ahead, Euroz Hartleys is bullish on the potential for BCI’s Mardie Salt Project, located in Western Australia. The project covers some 115 square kilometres on the Pilbara coast. On completion, which is nearing, it will be the third-largest salt project in the world and the largest in Australia, producing 5.35 million tonnes per annum (Mtpa).

MCI is aiming to complete construction of the Mardie Salt Project inside the next half year. First sales are targeted for the end of the first quarter of calendar year 2027 (Q1 2027).

Should I buy the ASX All Ords mining stock today?

BCI announced the results of its June quarter update on 20 July.

In a report released on 11 August, Euroz Hartleys noted, “Development is now 85% complete, with $1.19bn spent to date and the remaining $258m construction cost (+ WC) fully funded by $423m of liquidity.”

The wealth manager added:

Importantly, BCI has commenced salt crystallisation, with 49kt of crystallised salt on hand at 30 Jun ’26, marking a key transition from construction towards operations. BCI expects to be operationally ready for FSOS in Q1 CY27, although first harvest remains weather dependent, with adverse conditions potentially delaying timing by up to 6 months.

Summarising their buy rating on the ASX All Ords mining stock, Euroz Hartleys’ analysts said:

At salt-only steady-state 5.35 mtpa full run-rate (from FY30 on our numbers), BCI is forecast to generate ~$250m EBITDA p.a. with a long asset life (60+yrs) given ‘unlimited’ reserves (seawater), with low sustaining capex providing strong FCF [free cash flow] generation (~$190m p.a.) and the basis for material shareholder returns (assuming 80-100% payout).

Tolling opportunities (i.e. nearby stranded iron ore) from the spare capacity at the 100%-owned 20mtpa Cape Preston West Port offers an additional material revenue stream (>$100m p.a. potential) and SOP (and other waste stream/salt bitterns products) provide very real medium-term upside for staged earnings growth on top of the salt (+$70m EBITDA p.a.).

Euroz Hartleys has a price target of 60 cents per share on the ASX All Ords mining stock.

That represents an upside of more than 30% from the current MCI Minerals share price.

The post Why this $1.4 billion ASX All Ords mining stock is tipped to jump 30% appeared first on The Motley Fool Australia.

More reading

• Brokers name 3 ASX shares to buy with gains of up to 75%

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.